Physician profile
Mina Hignutt
NPI 1508182817
$3,602.87
in general payments reported to CMS, 2019-2025
30 companies · $617 in 2025
The $617 reported for 2025 was more than what 97% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $729 · 2023: $856 · 2024: $666 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.79 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $320.97 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $286.18 | 2021-2025 | |
| Organon LLC | $222.64 | 2022-2025 | Nexplanon, Nuvaring, Jada System |
| Sumitomo Pharma America, INC. | $218.30 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $178.72 | 2021-2023 | Phexxi |
| Astellas Pharma US INC | $168.59 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $158.08 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $151.46 | 2021-2022 | |
| Coopersurgical, INC. | $146.36 | 2023-2024 | Paragard T 380a, Paragard T 380a, Sos |
| Biogen, INC. | $111.66 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $93.11 | 2021 | |
| Pfizer INC. | $80.62 | 2022-2025 | |
| Mylan Pharmaceuticals INC. | $80.23 | 2021-2022 | |
| Shield Therapeutics INC | $64.72 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.06 | 2021-2024 | Gardasil, Gardasil 9 |
| Aspira Women'S Health INC | $59.83 | 2022-2024 | Ova1 |
| Myriad Women'S Health, INC. | $59.43 | 2023 | Myrisk |
| Baxter Healthcare | $55.24 | 2023 | Perclot |
| Ethicon US, LLC | $53.75 | 2021-2023 | Harmonic, Stratafix |
| Therapeuticsmd, INC. | $51.28 | 2021-2022 | |
| Avion Pharmaceuticals | $40.15 | 2021 | |
| Millicent US INC | $33.52 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Viiv Healthcare Company | $29.22 | 2025 | Apretude |
| Hologic Sales and Service, LLC | $26.49 | 2021-2024 | Novasure, Myosure Tissue Removal Device |
| Boston Scientific Corporation | $19.80 | 2022 | |
| Medtronic, INC. | $17.08 | 2024 | Venaseal |
| Daiichi Sankyo INC. | $15.82 | 2021 | |
| Smith+Nephew, INC. | $14.75 | 2024 | Pico 7, Pico 14 |
| Exact Sciences Corporation | $14.02 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Hignutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.